Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma

November 30, 2016

Join Prashant Kapoor, MD and Shaji Kumar, MD from Mayo Clinic Cancer Center as they present their expertise on a range of cases pertaining to multiple myeloma.

Many factors need to be considered when determining the optimal multiple myeloma (MM) treatment: age, prognostic factors, comorbidities, toxicity profiles, response to prior therapy and previous relapses. Moreover, a variety of available supportive care measures targeting adverse symptoms related to MM or MM therapy have to be tailored to a specific patient. Therefore, the key in maximizing positive treatment and supportive care outcomes for patients with MM lies in careful choice of individualized treatment regimens along with early recognition and management of treatment or MM-associated adverse events. It is critical that health care providers are up-to-date with the most current evidence-based recommendations to be able to make best practice decisions in this complex environment.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Evaluate the multidisciplinary aspects and key clinical considerations to optimize diagnosis and management of patients with multiple myeloma.
  • Enhance awareness of new evidence-based therapeutic options for multiple myeloma.
  • Tailor supportive care measures to individual patients.
Additional information
Supporters: 

This educational activity is supported by educational grants from Astellas; AstraZeneca; Bayer Healthcare Pharmaceuticals Inc.; Celgene Corporation; Eisai; Genomic Health, Inc.; Janssen Biotech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Sanofi-Genzyme; and Takeda Oncology. This activity is supported by educational funding provided by Amgen. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This educational activity is supported by an unrestricted education grant from Exelixis, Inc. This educational activity is supported by an independent educational grant from Merck.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
11/29/2016
Course expires: 
01/18/2017
Event starts: 
11/30/2016 - 12:30pm EST
Event ends: 
11/30/2016 - 1:30pm EST
Cost:
$0.00

Prashant Kapoor, MD
Mayo Clinic Cancer Center

Shaji Kumar, MD
Mayo Clinic Cancer Center

 

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below have disclosed the following relevant financial relationships:

Prashant Kapoor, MD, FACP
Amgen Inc.: Grant/Research Support
Celgene Corporation: Grant/Research Support
sanofi-aventis U.S.: Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support

Shaji K. Kumar, MD
Abbott Laboratories: Grant/Research Support
Amgen Inc.: Grant/Research Support; Scientific Advisor
Bristol-Myers Squibb Company: Scientific Advisor
Celgene Corporation: Grant/Research Support; Scientific Advisor
GlycoMimetics: Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Kesios Therapeutics: Consulting Fees, Honoraria
Novartis Pharmaceuticals Corporation: Grant/Research Support
NOXXON Pharma AG: Consulting Fees, Honoraria
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
SkylineDx: Consulting Fees, Honoraria
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support; Scientific Advisor

The activity planning staff listed below has no relevant financial relationships to disclose:
Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser

The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:
Rashmi Kumar, PhD; Dorothy Shead, MS

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 1.0 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour.  Activity Code: I00023954; Approval #: 160004413

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge

National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-16-106-L01-P

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing